PARTNER: randomised, phase 2/3 trial evaluating safety & efficacy of adding olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Abraham, J Vallier, L Qian, W Machin, A Grybowicz, L Thomas, S Weiss, M Harvey, C McAdam, K Hughes-Davies, L
Abraham, J
Vallier, L
Qian, W
Machin, A
Grybowicz, L
Thomas, S
Weiss, M
Harvey, C
McAdam, K
Hughes-Davies, L
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Abraham J, Vallier A, Qian W, Machin A, Grybowicz L, Thomas S, et al. PARTNER: randomised, phase 2/3 trial evaluating safety & efficacy of adding olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. Br J Cancer. 2018;119(11):45.